Thirty- and 90-day survival were better among patients treated through surgical resection for their non–small cell lung cancer (NSCLC) in Medicaid-expansion states vs nonexpansion states, according...
Lyudmila A. Bazhenova, MD, medical oncologist, professor, medicine, the University of California San Diego (UCSD) Moores Cancer Center, discusses factors to consider when navigating the use of...
Biagio Ricciuti, MD, thoracic medical oncologist, staff scientist II, Department of Medicine, Dana-Farber Cancer Institute, discusses the association between PD-L1 expression levels and long-term survival with anti–PD-L1...
The proportion of certain blood immune cell types, predominately T cells and neutrophils, was linked with response to immune checkpoint inhibitors (ICIs) in patients with non–small...
Machine learning–aided prediction models are capable of learning the relationship between clinical features and later development of brain metastases (BM) in patients with non-small cell lung...
Long-term data from the CHRYSALIS trial (NCT02609776) continued to demonstrate the clinical benefit of amivantamabvmjw (Rybrevant), according to study results presented at the European Lung Cancer...
Recent Comments